

DLL3
Catalog # PVGS1816**Specification**

DLL3 - Product InformationPrimary Accession [A0A2K5WSR1](#)**Species**
Cynomolgus**Sequence**
Ala27-Ala477**Purity**
> 95% as determined by Bis-Tris PAGE**Endotoxin Level**
Less than 1EU per µg by the LAL method.**Biological Activity**
Immobilized DLL3, His, Cynomolgus (Cat.No.: Z03946) at 0.2 µg/ml (100 µl/Well) on the plate can bind Anti-DLL3 Antibody, hFc Tag**Expression System**
HEK293**Theoretical Molecular Weight**
48.80 kDaFormulation **Lyophilized from 0.22 µm filtered solution in 20mM Tris, 200mM NaCl, 200mM L-arginine (pH 8.5).****Reconstitution**
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O more than 100 µg/ml.**Storage & Stability**
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.**DLL3 - Additional Information****Target Background**
Delta-like ligand 3 (DLL3) is an inhibitory Notch ligand. It is highly expressed on the surface of Small cell lung cancer (SCLC) and other neuroendocrine tumors. And its expression promotes SCLC migration and invasion. DLL3 agents are evaluated in several ongoing clinical studies in SCLC and other neuroendocrine tumors.

DLL3 - Protein Information

DLL3 - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

DLL3 - Images